Liu, Y., Lin, N., Yi, S., Huang, H., Guo, Y., Zhang, Q., . . . Zhu, J. (2025). Pirtobrutinib in Chinese patients with relapsed or refractory B‐cell malignancies: A single‐arm, open‐label, phase 2, multicenter trial. Wiley. https://doi.org/10.1002/ijc.35339
Chicago Style (17th ed.) CitationLiu, Yanyan, et al. Pirtobrutinib in Chinese Patients with Relapsed or Refractory B‐cell Malignancies: A Single‐arm, Open‐label, Phase 2, Multicenter Trial. Wiley, 2025. https://doi.org/10.1002/ijc.35339.
MLA (9th ed.) CitationLiu, Yanyan, et al. Pirtobrutinib in Chinese Patients with Relapsed or Refractory B‐cell Malignancies: A Single‐arm, Open‐label, Phase 2, Multicenter Trial. Wiley, 2025. https://doi.org/10.1002/ijc.35339.
Warning: These citations may not always be 100% accurate.